Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant durvalumab ± bevacizumab after curative therapy for high-risk hepatocellular carcinoma
jRCT2080224793Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Durvalumab monotherapy, Durvalumab + bevacizumab and Placebo (3 arms). Started Jul 2019; status: completed.
02
Drugs
durvalumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080224793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224793.